Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid

  • Marianna Fontana1, 2,
  • Thomas A. Treibel2, 3,
  • Ana Martinez-Naharro1,
  • Stefania Rosmini3,
  • Raymond Y. Kwong4,
  • Julian D. Gillmore1,
  • Philip N. Hawkins1 and
  • James C. Moon2, 3Email author
BMC Medical ImagingBMC series – open, inclusive and trusted201717:3

DOI: 10.1186/s12880-016-0173-5

Received: 13 July 2016

Accepted: 21 December 2016

Published: 7 January 2017

Abstract

Background

Cardiac amyloidosis is a progressive but underdiagnosed and underappreciated cause of heart failure. In the last few years, cardiovascular magnetic resonance (CMR) has become the gold standard for non invasive diagnosis of cardiac amyloidosis with the characteristic subendocardial late gadolinium enhancement.

Case presentation

We describe a case of a patient who, in the process of aligning protocols for a trial between different centers, had a paired study with two different contrast agents, Dotarem® and MultiHance®. MultiHance® surprisingly failed to demonstrate the characteristic imaging pattern, showing only non specific late gadolinium enhancement at the inferior right ventricular insertion point and different myocardial extracellular volume fraction compared to the one obtained with Dotarem®. MultiHance® is used by many centres, because its partial blood protein binding is a strength for MR angiography, but late gadolinium enhancement, particularly non-ischemic, appears to be compromised.

Conclusions

This case report suggests that contrast agents should be selected with caution, especially with new therapies lining up for amyloid and CMR being used as exploratory end point in clinical trials.

Keywords

Case report Amyloidosis CMR Contrast

Background

In the last decade, cardiovascular magnetic resonance (CMR) has grown dramatically and in amyloidosis has become the gold standard for non invasive diagnosis of cardiac involvement with the characteristic subendocardial late gadolinium enhancement (LGE) [1]. The number of new referrals for cardiac amyloidosis has significantly increased in the last few years, with the diagnosis being based on CMR and the characteristic LGE. New contrast agents favoured for their high relaxivity related to blood protein binding, [2] have become available but no one has ever tested the diagnostic performance of these new agents in infiltrative disease.

Case presentation

A 77-year old man presented with breathlessness and weight loss. Endoscopy and duodenal biopsy showed amyloid deposits, subtyped as transthyretin type (TTR). Investigations excluded a plasma cell dyscrasia, and showed atrial fibrillation on ECG (Fig. 1), and moderately increased wall thickness with moderate to severe diastolic dysfunction on echocardiography (Fig. 2, videos available as Additional files 1 and 2). TTR gene sequencing showed no mutation so the diagnosis was that of wild-type ATTR amyloidosis (senile systemic amyloidosis). Cardiac involvement, though likely, was not unequivocal as age/hypertension can confound. Technetium-labelled bone scintigraphy and CMR were performed. Scintigraphy demonstrated grade 2 myocardial uptake, highly specific for cardiac amyloidosis. Cine CMR imaging supported the echocardiographic and scintigraphy findings. Tissue characterization showed clear amyloidosis with elevated native myocardial T1 (ShMOLLI, 1072 ms, normal 960 ms+/-30 ms) and, after contrast (Gadoterate meglumine, 0.1 mmol/kg, gadolinium-DOTA, Dotarem® Guerbet S.A. France), abnormal gadolinium kinetics on TI scout (nulling of the myocardium before the blood) and diffuse biventricular subendocardial LGE (Fig. 2) [1]. The extracellular volume fraction (ECV) at 15 min was 0.53.
Fig. 1

Twelve lead ECG at presentation showing atrial fibrillation

Fig. 2

Parasternal long axis (left) and apical four-chamber (right) views echocardiography images. Videos are available as Additional files 1 and 2

Two weeks later, the CMR was repeated (same scanner and team with no changes in the patient regarding treatment or disease status) within the screening tests of a clinical trial, this time with a different contrast agent, gadobenate dimeglumine (0.1 mmol/kg, gadolinium-BOPTA, MultiHance®, Bracco, Milan, Italy). The cines and native T1 findings were the same (Fig. 3). The LGE however was markedly different – the subendocardial LGE so characteristic of amyloidosis was not visible, even with phase-sensitive inversion recovery (PSIR). There was just non-specific right ventricle insertion point LGE (Fig. 4). The ECV at 15 min obtained using Gd-BOPTA (MultiHance®) was now lower – 0.45 compared to 0.53 with gadolinium-DOTA (Dotarem®) (same acquisition time after contrast administration). This difference is higher than the expected variability of the technique. Prior publications demonstrate the ECV to be stable to a standard deviation of 0.02 (0.03 for amyloid); [3] here a 0.08 difference with contrast agent is recorded.
Fig. 3

Short axis ShMOLLI T1 mapping images pre-contrast (top) and post-contrast (bottom) with gadolinium-DOTA, Dotarem® (a) and with gadolinium-BOPTA, MultiHance® (b). Myocardial T1 post-contrast = 486 ms and blood T1 post-contrast =506 ms 15 min after gadolinium-DOTA, Dotarem®; and myocardial T1 post-contrast = 344 ms and blood T1 post-contrast = 287 ms 15 min after gadolinium-BOPTA, MultiHance®

Fig. 4

CMR end-diastolic cine (a); late gadolinium images with Magnitude-FLASH (b) and late gadolinium images with PSIR-FLASH (c) after gadolinium-DOTA, Dotarem® showing the classic amyloid global, subendocardial late gadolinium enhancement pattern; late gadolinium images with Magnitude-FLASH (d) and late gadolinium images with PSIR-FLASH (e) after gadolinium-BOPTA MultiHance®, showing no features of amyloid

Discussion

Gd-BOPTA (MultiHance®) is an ionic linear chelate favoured for its high relaxivity related to blood protein binding, [2] which also makes it a partially “intra-vascular” contrast agent. Here, paired scanning performed serendipitously for a clinical trial failed to demonstrate the characteristic pattern of myocardial amyloidosis, and performed poorly compared to gadoterate meglumine. MultiHance® is widely used for CMR. This effect was unexpected – but theoretical concerns had been raised for ECV mapping with protein bound contrast agents [4]. Due to difference in relaxivity between the contrast agents, some Authors proposed the use of a lower dose of Gd-BOPTA for reaching similar T1 and ECV values. In this case the same dose was used for both contrasts and this could explain in part the differences observed. In this case, the use of MultiHance® did not affect the diagnosis, but reporting the MultiHance® CMR in isolation without the previous work-up by the National Amyloid Centre could have conceivably led to a misdiagnosis.

Conclusion

We suggest that protein bound agents for interstitial enhancement of non-ischaemic cardiomyopathy (myocardium, ECV measurement) should be used with caution whilst further work is undertaken as the diagnostic performance may not be the same as non-protein bound variants.

Abbreviations

CMR: 

Cardiovascular magnetic resonance

ECG: 

Electrocardiogram

ECV: 

Extracellular volume

Gd: 

Gadolinium

LGE: 

Late gadolinium enhancement

PSIR: 

Phase Sensitive Inversion Recovery

ShMOLLI: 

Shortened Modified Look-Locker Inversion recovery

TTR: 

Transthyretin type

Declarations

Acknowledgments

Not applicable.

Funding

No funding.

Availability of data and materials

If asked, I will provide or fully cooperate in obtaining and providing the original data on which the manuscript is based so the editors or their designates can examine it.

Authors’ contributions

MF and JCM have made substantial contributions to conception and design of the case, have been involved in drafting the manuscript and revising it critically for important intellectual content and have given final approval of the version to be published. TAT, AMN, RYK, JDG and PNH have made substantial contributions to conception and design of the case, have been involved in revising the manuscript critically for important intellectual content and have given final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

The authors do hereby declare that all illustrations and figures in the manuscript are entirely original and do not require reprint permission.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Amyloidosis Centre, University College London, Royal Free Hospital
(2)
Institute of Cardiovascular Science, University College London
(3)
Barts Heart Centre, West Smithfield
(4)
Non-Invasive Cardiac Imaging, Cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School

References

  1. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.View ArticlePubMedGoogle Scholar
  2. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, Schick F. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Investig Radiol. 2006;41(3):213–21.View ArticleGoogle Scholar
  3. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S, Roberts N, Moon JC. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14:88.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement